β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models | Zendy

Gianina Demarchi | Zendy; S Valla | Zendy; Sofía Perrone | Zendy; Agustina Chimento | Zendy; N. Bonadeo | Zendy; Daiana L. Vitale | Zendy; Fiorella M. Spinelli | Zendy; Andrés Cervio | Zendy; Gustavo Sevlever | Zendy; Laura Alaniz | Zendy; Silvia Berner | Zendy; Carolina Cristina | Zendy

Open Access

β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models

Author(s) -

Gianina Demarchi,

S Valla,

Sofía Perrone,

Agustina Chimento,

N. Bonadeo,

Daiana L. Vitale,

Fiorella M. Spinelli,

Andrés Cervio,

Gustavo Sevlever,

Laura Alaniz,

Silvia Berner,

Carolina Cristina

Publication year - 2022

Publication title -

tumor biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.055

H-Index - 84

eISSN - 1423-0380

pISSN - 1010-4283

DOI - 10.3233/tub-211500

Subject(s) - prolactinoma , temozolomide , prolactin , cancer research , membrane , pituitary tumors , catenin , medicine , chemistry , tumor cells , pituitary neoplasm , endocrinology , microbiology and biotechnology , biology , glioblastoma , signal transduction , biochemistry , pituitary gland , wnt signaling pathway , hormone

Prolactinomas are the most frequent pituitary tumor subtype. Despite most of them respond to medical treatment, a proportion are resistant and become a challenge in clinical management. Wnt/β-Catenin pathway has been implicated in several cancers including pituitary tumors and other sellar region malignancies. Interestingly, Wnt/β-Catenin inhibition augments the cytotoxicity of the chemotherapeutic agent Temozolomide (TMZ) in different cancers. TMZ is now being implemented as rescue therapy for aggressive pituitary adenoma treatment. However, the molecular mechanisms associated with TMZ action in pituitary tumors remain unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research